302 related articles for article (PubMed ID: 36357681)
1. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
Ossenkoppele R; Pichet Binette A; Groot C; Smith R; Strandberg O; Palmqvist S; Stomrud E; Tideman P; Ohlsson T; Jögi J; Johnson K; Sperling R; Dore V; Masters CL; Rowe C; Visser D; van Berckel BNM; van der Flier WM; Baker S; Jagust WJ; Wiste HJ; Petersen RC; Jack CR; Hansson O
Nat Med; 2022 Nov; 28(11):2381-2387. PubMed ID: 36357681
[TBL] [Abstract][Full Text] [Related]
2. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
[TBL] [Abstract][Full Text] [Related]
3. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O
Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
5. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.
Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889
[TBL] [Abstract][Full Text] [Related]
6. Predicting future rates of tau accumulation on PET.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Whitwell J; Josephs K; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
Brain; 2020 Oct; 143(10):3136-3150. PubMed ID: 33094327
[TBL] [Abstract][Full Text] [Related]
7. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
8. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
Lowe VJ; Wiste HJ; Senjem ML; Weigand SD; Therneau TM; Boeve BF; Josephs KA; Fang P; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR
Brain; 2018 Jan; 141(1):271-287. PubMed ID: 29228201
[TBL] [Abstract][Full Text] [Related]
9. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
10. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity.
Costoya-Sánchez A; Moscoso A; Silva-Rodríguez J; Pontecorvo MJ; Devous MD; Aguiar P; Schöll M; Grothe MJ;
JAMA Neurol; 2023 Oct; 80(10):1051-1061. PubMed ID: 37578787
[TBL] [Abstract][Full Text] [Related]
11. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
12. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
13. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
14. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal tau PET in ageing and Alzheimer's disease.
Jack CR; Wiste HJ; Schwarz CG; Lowe VJ; Senjem ML; Vemuri P; Weigand SD; Therneau TM; Knopman DS; Gunter JL; Jones DT; Graff-Radford J; Kantarci K; Roberts RO; Mielke MM; Machulda MM; Petersen RC
Brain; 2018 May; 141(5):1517-1528. PubMed ID: 29538647
[TBL] [Abstract][Full Text] [Related]
16. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
[TBL] [Abstract][Full Text] [Related]
17. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
[TBL] [Abstract][Full Text] [Related]
18. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
[TBL] [Abstract][Full Text] [Related]
19. Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer's disease.
Cai Y; Du J; Li A; Zhu Y; Xu L; Sun K; Ma S; Guo T;
Alzheimers Res Ther; 2023 Feb; 15(1):30. PubMed ID: 36750884
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
